A pivotal comparative clinical study evaluating Empagliflozin against Pioglitazone in non-diabetic patients with Non-alcoholic Steatohepatitis (NASH) was published on 2022-01-01. This study provides insights into the potential role of Empagliflozin in managing this liver condition.
Background
The published study investigated Empagliflozin in the context of Non-alcoholic Steatohepatitis (NASH). This condition was studied specifically in non-diabetic patients, comparing Empagliflozin's effects against Pioglitazone. NASH is a form of Non-alcoholic fatty liver disease (NAFLD).
Trial design
The study was a comparative clinical study that evaluated Empagliflozin against Pioglitazone. It specifically enrolled non-diabetic patients diagnosed with Non-alcoholic Steatohepatitis (NASH). The objective was to compare the clinical outcomes between these two treatments in this patient population.
What this means
The publication of this comparative clinical study indicates that research is ongoing into potential treatments for Non-alcoholic Steatohepatitis (NASH), particularly for non-diabetic patients. While specific results are not detailed in the provided information, the comparison between Empagliflozin and Pioglitazone suggests an exploration of different therapeutic approaches for this challenging liver condition. Clinicians and researchers will look to the full publication for detailed efficacy and safety data to understand the implications for patient care.
Source
The information for this article is based on a pivotal publication indexed on PubMed on 2022-01-01. The study, titled "Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis," was made available via pubmed.ncbi.nlm.nih.gov.